BioInvent International AB (publ) appoints Vice President

BioInvent International AB (publ) appoints Vice President Lund, Sweden: In connection with the merger between BioInvent International AB (publ) and its subsidiaries BioInvent Production AB and BioInvent Therapeutic AB, the board of directors has today appointed Cristina Glad (50) as Vice President of the company, starting today. Cristina, Doctor of Science, biochemistry and MBA, has worked within the BioInvent group since 1987 inter alia as Director of Manufacturing and Business Development 1990 - 1997 and holds since 1997 the position of President of BioInvent Production AB. For more information please contact BioInvent International AB Buchanan Communications Svein Mathisen Nicola How President and CEO Tel: +44 20 7466 5000 Tel.: +46 46 286 85 67 Mobile: +46 708 97 82 13 E-mail: sm@bioinvent.com Notes to Editors: BioInvent International AB, listed on the O-list of the Swedish Exchange, is a biotechnology company devoted to providing state-of-the- art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes that are ready to be screened against desired antigens. n-CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein-based drugs through a state-of-the-art cGMP-certified facility further underpin its competitiveness in the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified manufacturing facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total of 125 people. For further information, see www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT01010/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT01010/wkr0002.pdf

About Us

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer. The company has unique expertise in antibody drug development from initial concept to late clinical phase. The antibody library n-CoDeR and the screening tool F.I.R.S.T. are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

Subscribe